en · de · es · fr · pt
cardarine-notes.peptides3626.com › Blog › Preclinical Findings And Safety Signals — Evidence Review

Preclinical Findings And Safety Signals — Evidence Review

By Editorial Desk · published 2026-03-29 · last reviewed 2026-05-14 · Blog

The short version of carcinogenicity fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.

Preclinical Findings and Safety Signals

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Mechanism and Detection Methods

Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.

Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid metabolism
Preclinical effectIncreased fatty acid oxidationObserved in rodent studies
Key safety signalTumors in rodents after long-term exposureContributed to halted clinical development
Human trial statusNo approved product; development stoppedLimited short-term metabolic data
Sport regulatory statusProhibited at all timesWADA hormone and metabolic modulators class

Mechanism and Safety Research

GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Related pages on this site

Cardarine as Investigational PPARδ Agonist

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

Notes from published material

=== Israel trip === During a July 2026 trip to Israel, Chabad "outreach figure" Yossi Farro presented Peters with a "custom necklace" which shows the Star of David fused with the OpenAI logo. The moment was considered the "latest flashpoint" in a debate over how the Jewish community should engage with controversial online figures. Farro joked online that the "mashup" amounted to the AI company's logo "mogging" the Jewish star. The two switched restaurants mid-meal once Peters realized the one they had chosen was not kosher. Farro posted about the trip, saying Peters "is loving Israel and Israel is loving him." "Peters's manager is Jewish," Farro further explained, "and the rabbi of the Chabad community connected to the manager thought it would be worthwhile to introduce us. Thank God, we connected." The Times of Israel reported that Peters had been seen talking to prime minister Benjamin Netanyahu's adviser Topaz Luk at a Tel Aviv nightclub. Israeli influencers who appeared on Peters's streams, Shira Braun and Shira Klein, were reprimanded and demoted from their positions by the Israel Defense Forces.

== Legacy == David Lipman, director of the National Center for Biotechnology Information, has called Dayhoff the "mother and father of bioinformatics". Her seminal contributions as the mother of the science of bioinformatics, now routinely used as part of the process for naming bacteria, were acknowledged with a bacterium being named after her in 2020, Enemella dayhoffiae. Dayhoff was inducted into the Maryland Women's Hall of Fame in March 2026.

The Guatemalan Air Force had 30 P-51D Mustangs in service from 1954 to the early 1970s. Haiti Haiti had four P-51D Mustangs when President Paul Eugène Magloire was in power from 1950 to 1956, with the last retired in 1973–1974 and sold for spares to the Dominican Republic. Indonesia

Purification in a chemical context is the physical separation of a chemical substance of interest from foreign or contaminating substances. Pure results of a successful purification process are termed isolate. The following list of chemical purification methods should not be considered exhaustive.

Sources: en.wikipedia.org

Background from the literature

=== Nucleus === Granzyme B has many substrates located in the nucleus. Granzyme B can cleave PARP (poly ADP ribose polymerase) and DNA PK (DNA protein kinase) to disrupt DNA repair and retroviral DNA integration. Granzyme B can also cleave nucleophosmin, topoisomerase 1 and nucleolin to prevent viral replication. Granzyme B can cleave ICP4 from the HSV 1 virus which is an essential protein used for gene transactivation and NUMA (Nuclear mitotic apparatus protein) can be cleaved to prevent mitosis. Granzyme B can also cleave DBP (DNA Binding Protein) into a 50 kDa fragment and then into an additional 60 kDa indirectly through the caspases it activates.

== Olfactory perception == The properties of a compound relating to human olfactory perception includes its odour quality, threshold and intensity as a function of its concentration. The odour quality of a (odour-active) compound is assessed using odour descriptors in sensory descriptive analyses. It shows the sensory–chemical relationship in volatile compounds. The odour quality of a compound may change with its concentration. The absolute threshold of a compound is the minimum concentration at which it can be detected. In a mixture of volatile compounds, only the proportion of compounds present at concentrations above their threshold contribute to the odour. This property can be represented by the odour threshold (OT), the minimum concentration at which the odour is perceived by 50% of a human panel without determining its quality, or the recognition threshold, the minimum concentration at which the odour is perceived and can be described by 50% of a human panel. The intensity of perception of a compound is positively correlated with its concentration. It is represented by the unique psychometric or concentration-response function of the compound.

Parkinson's disease (PD) is a neurodegenerative disorder that progresses over time, marked by bradykinesia (slowed movements), tremor (rhythmic shaking), and stiffness. As the condition worsens, patients may experience postural instability, finding it difficult to balance and maintain upright posture. Worldwide, Parkinson's disease affects around 3% people over 65 years of age. PD's incidence and prevalence varies widely across geographic regions and shows spatial clustering, including higher rates in North America and Europe than in Asia and Africa. Parkinson's disease (PD) involves the gradual degeneration of dopamine producing neurons in a brain region called the substantia nigra and other related cell groups in the brainstem. This is accompanied by the accumulation of misfolded proteins such as alpha-synuclein. Alpha-synuclein is normally found in the presynaptic terminals of neurons. If alpha-synuclein is mis-folded and not cleared from cells by cellular degradation systems, it can build up to form clumps of proteins called Lewy bodies and Lewy neurites. Accumulation stimulates the release of pro-inflammatory molecules by the microglia, a protective response that can cause inflammation and neuronal damage if it becomes chronic. Neuroinflammation causes the blood-brain barrier (BBB) to become more permeable, allowing dangerous substances and inflammatory cells to enter the brain and interfere with metabolic functions. Dysfunction in mitochondria, which are central to cellular energy production, increases oxidative stress and cell death.

Sources: en.wikipedia.org

Frequently asked questions

What did animal studies show?

Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.

Has cardarine been tested in humans?

Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.

Does cardarine improve athletic performance in people?

Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.

What receptor does cardarine target?

Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.

Network